Ketamine, given intravenously, might be the most important breakthrough in antidepressant treatment in decades.
Ketamine and Esketamine for Treatment-Resistant Depression
Ketamine used for infusion therapy is composed of K-ketamine and S-ketamine, a widely-used medicine serving as an anesthetic. Esketamine, the S-ketamine, is given intranasally.
Administered with a low dose, they work on the neurotransmitters in the brain differently from traditional antidepressants like SSRIs. They are more successfully fast-acting in reducing the symptoms of depression and suicidal ideation. Some medical professionals regard them as lifesavers for Treatment-Resistant patients with Depression.
Esketamine had the FDA (Food and Drug Administration) approval in 2019 to address Treatment-Resistant Depression.
There exists no medicine that is “merely” good or bad: drugs are bad when they are used incorrectly.
Both Ketamine and Esketamine are hallucinogenic, and their misuse can cause medical peril. A careful examination of the individual case remains obligatory to choose the right candidate and protocol. The administration of Ketamine and Esketamine should occur in controlled settings with close, long-term monitoring.